Search Results - "Papandreou, C. N."

Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients by Vlachostergios, P J, Gioulbasanis, I, Kamposioras, K, Georgoulias, P, Baracos, V E, Ghosh, S, Maragouli, E, Georgoulias, V, Papandreou, C N

“…Cancer patients frequently suffer from weight loss and systemic inflammation in the context of advanced disease, which is related to adverse outcome…”
Get more information

Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours by FIZAZI, K, PROW, D. M, PAGLIARO, L. C, LOGOTHETIS, C. J, AMATO, R. J, DO, K-A, WANG, X, FINN, L, KIM, J, DALIANI, D, PAPANDREOU, C. N, TU, S-M, MILLIKAN, R. E

“…Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this phase II study was to assess the…”
Get full text

Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG) by Koutsoukos, Konstantinos, Tzannis, Kimon, Christodoulou, Christos, Karavasilis, Vasilios, Bakoyiannis, Charalambos, Makatsoris, Thomas, Papandreou, C. N., Pectasides, Dimitrios, Dimopoulos, Meletios A., Bamias, Aristotelis

“…Purpose Following the establishment of adjuvant carboplatin in stage I testicular seminoma as a standard, we adopted this treatment for all stage I seminoma…”
Get full text

Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid by HOFFMAN, A. D, ENGELSTEIN, D, BOGENRIEDER, T, PAPANDREOU, C. N, STECKELMAN, E, DAVE, A, MOTZER, R. J, DMITROVSKY, E, ALBINO, A. P, NANUS, D. M

“…The differentiation and growth suppressive effects of retinoic acid are mediated through retinoic acid nuclear receptors (RARs and RXRs), which are…”
Get full text

Bevacizumab in advanced cervical cancer by Vlachostergios, P. J., Papandreou, C. N.

Get full text

Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme ( ) gene in patients with renal cancer by USMANI, B. A, JANECZKO, M, SHEN, R, MAZUMDAR, M, PAPANDREOU, C. N, NANUS, D. M

“…The angiotensin I-converting enzyme (ACE) contains an insertion/deletion (I/D) polymorphism, with the DD genotype associated with benign renal diseases. The…”
Get full text

Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue by Bogenrieder, Thomas, Finstad, Connie L., Freeman, Ronald H., Papandreou, Christos N., Scher, Howard I., Albino, Anthony P., Reuter, Victor E., Nanus, David M.

“…BACKGROUND Cell‐surface peptidases are ectoenzymes which regulate the access of bioactive peptides to their receptors on cell membranes. Abnormalities in their…”
Get full text

Markers of androgen-independent progression of prostatic carcinoma by Daliani, D, Papandreou, C N

“…Prostate cancer (PCa) remains the most common cancer and the second leading cause of cancer mortality in men in the United States. The evolution from a…”
Get more information

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer by Vlachostergios, P. J., Gioulbasanis, I., Ghosh, S., Tsatsanis, C., Papatsibas, G., Xyrafas, A., Hatzidaki, E., Vasiliou, C., Kamposioras, K., Agelaki, S., Margioris, A. N., Nasi, D., Georgoulias, V., Papandreou, C. N.

“…Objective Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the…”
Get full text

Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in “thin” and “thick” tissue sections by Kouvaras, E, Papandreou, C.N, Daliani, D.D, Athanasiadis, A, Koukoulis, G.K

“…Abstract One presumed drawback of performing fluorescence in situ hybridization on routine tissue sections for HER-2 status evaluation in breast carcinomas is…”
Get full text

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial by Tu, Shi-Ming, Millikan, Randall E, Mengistu, Bayabel, Delpassand, Ebrahim S, Amato, Robert J, Pagliaro, Lance C, Daliani, Danai, Papandreou, Christos N, Smith, Terry L, Kim, Jeri, Podoloff, Donald A, Logothetis, Christopher J

“…Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with…”
Get full text

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer by PAPANDREOU, Christos N, DALIANI, Danai D, KIM, Jeri, ADAMS, Julian, ELLIOTT, Peter, ESSELTINE, Dixie, PETRUSICH, Alexandria, DIERINGER, Pauline, PEREZ, Cherie, LOGOTHETIS, Christopher J, NIX, Darrell, HONG YANG, MADDEN, Timothy, XUEMEI WANG, PIEN, Christine S, MILLIKAN, Randall E, TU, Shi-Ming, PAGLIARO, Lance

“…To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5…”
Get full text

Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling by Sumitomo, M, Shen, R, Walburg, M, Dai, J, Geng, Y, Navarro, D, Boileau, G, Papandreou, C N, Giancotti, F G, Knudsen, B, Nanus, D M

“…Neutral endopeptidase 24.11 (NEP, CD10) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated…”
Get full text

Aminopeptidase A expression and enzymatic activity in primary human renal cancers by Nanus, D M, Bogenrieder, T, Papandreou, C N, Finstad, C L, Lee, A, Vlamis, V, Motzer, R J, Bander, N H, Albino, A P, Reuter, V E

“…The gp160 human kidney differentiation antigen is identical to human aminopeptidase A (APA), a zinc-dependent cell-surface metallopeptidase which hydrolyzes…”
Get more information

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression by Papandreou, Christos N, Usmani, Badar, Geng, Yiping, Bogenrieder, Thomas, Freeman, Ronald, Wilk, Sherwin, Finstad, Connie L, Reuter, Victor E, Powell, C. Thomas, Scheinberg, David, Magill, Catherine, Scher, Howard I, Albino, Anthony P, Nanus, David M

“…Neutral endopeptidase 24.11 (NEP) is a cell-surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates neuropeptides implicated in the…”
Get full text

Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers by Papandreou, Christos N., Bogenrieder, Thomas, Loganzo, Frank, Albino, Anthony P., Nanus, David M.

“…The p21 (WAF1/CIP1) cyclin-dependent kinase inhibitor is an M r 21,000 protein that can arrest cell growth by associating with and inhibiting cyclin-dependent…”
Get full text

Methylation of the Neutral Endopeptidase Gene Promoter in Human Prostate Cancers by Usmani, B A, Shen, R, Janeczko, M, Papandreou, C N, Lee, W H, Nelson, W G, Nelson, J B, Nanus, D M

“…Neutral endopeptidase 24.11 (NEP) is a cell surface peptidase expressed by prostatic epithelial cells that cleaves and inactivates neuropeptide growth factors…”
Get full text

Identification and characterization of two androgen response regions in the human neutral endopeptidase gene by Shen, Ruoqian, Sumitomo, Makoto, Dai, Jie, Hardy, Dianne O., Navarro, Daniel, Usmani, Badar, Papandreou, Christos N., Hersh, Louis B., Shipp, Margaret A., Freedman, Leonard P., Nanus, David M.

“…Transcription of the human neutral endopeptidase 24.11 (NEP) gene is androgen regulated in prostate cancer cells. Homology search identified a sequence…”
Get full text

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma by Daliani, Danai D., Papandreou, Christos N., Thall, Peter F., Wang, Xuemei, Perez, Cherie, Oliva, Rose, Pagliaro, Lance, Amato, Robert

“…BACKGROUND The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease…”
Get full text

Erratum to: Bortezomib represses HIF-1[alpha] protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells by Befani, C D, Vlachostergios, P J, Hatzidaki, E, Patrikidou, A, Bonanou, S, Simos, G, Papandreou, C N, Liakos, P

“…Issue Title: Understanding neuronal dysfunction and loss in neurodegenerative disease…”
Get full text